$BJDX

Bluejay Diagnostics, Inc.

Bluejay Diagnostics is a medical diagnostics company developing rapid, near-patient blood tests for critical care settings, with an initial focus on sepsis. Its Symphony platform combines an analyzer with single-use protein-detection cartridges and is designed to deliver laboratory-quality results in approximately 20 minutes. The first product candidate, Symphony IL-6, is an immunoassay intended to measure an inflammatory biomarker to help assess disease progression in critical care patients. The platform does not yet have U.S. regulatory clearance, and Bluejay has no revenue-generating operations. Bluejay plans to sell Symphony devices and diagnostic cartridges to critical care facilities, including hospital emergency rooms and intensive care units. Its planned model includes financing options for analyzers and recurring sales of single-use cartridges, which it intends to make the main source of revenue and gross profit. Sanyoseiko supports manufacturing of the analyzers and cartridges under contract. Bluejay is headquartered in Acton, Massachusetts.

1
0
3

No SEC Form 4 filings for $BJDX in the last 30 days.

See all $BJDX insider activity →
Low

Bluejay Diagnostics Reports $7.38 Million in Cash and Advances Clinical Milestones

Bluejay Diagnostics reported $7.38M in cash as of Q3 2026, up from $5.16M at year-end 2025. The company completed SYMON-II study enrollment and advanced Symphony platform manufacturing. It aims for FDA 510(k) submission in H1 2027, contingent on validation. Current funds should last until Q2 2027, with additional financing needed for long-term plans.

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

Bluejay Diagnostics, Inc. (BJDX): Submission of Matters to a Vote of Security Holders

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split ACTON, Mass., October 30, 2026 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient di

BJDX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning BJDX (Bluejay Diagnostics, Inc.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 3 bearish.

Recent BJDX coverage spans financial news, corporate actions and earnings.

What's driving BJDX

AlphAI scores every news story that mentions BJDX with an AI model for sentiment and relevance, and aggregates insider trades from Bluejay Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BJDX

Score
$BJDXMedContract

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update Completes SYMON-II clinical study enrollment and advances clinical validation activities Achieves critical manufacturing milestone ahead of contractual deadline, strengtheni

$BJDXMedShareholder vote

Bluejay Diagnostics, Inc. (BJDX): Submission of Matters to a Vote of Security Holders

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Exhibit 99.1 Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split ACTON, Mass., October 30, 2026 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient di

Four Bluejay shares will become one on Nov. 3

Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split, effective November 3, 2026. The company's common stock will trade under the same symbol, BJDX, with a new CUSIP number. Shareholders with certificates will receive exchange instructions, while others will see changes reflected in their accounts. Bluejay focuses on medical diagnostics, including its Symphony™ System for sepsis triage, which awaits FDA approval.

Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, Mass. October 13, 2026 — Bluejay Diagnostics, In

A cartridge site for a sepsis test is set up ahead of Bluejay's Oct. 23 deadline.

Bluejay Diagnostics (NASDAQ:BJDX) completed a manufacturing site for its Symphony™ sepsis test cartridges ahead of the October 23, 2026 deadline. The site, established under its agreement with Toray, is part of a strategy to diversify manufacturing with SanyoSeiko in Japan and ALURIS in the U.S. This milestone reduces commercialization risk as the company advances toward regulatory submission.

$BJDXMedContract· supplier

Bluejay Diagnostics, Inc. (BJDX): Entry into a Material Definitive Agreement

Bluejay Diagnostics, Inc. (BJDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets Partnership Establishes Federal Distribution and Co-Marketing Framework Across VA, DoD, Military Health Systems and Other Government Healthcare

$BJDXMedAI 8/10

5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara

Bluejay Diagnostics (BJDX) partnered with Lovell Government Services for federal healthcare market access, trading at $1.05, up 27.4%. Pharvaris (PHVS) reported 83% attack rate reduction in HAE study, trading at $37.82, up 7.02%. Roivant (ROIV) showed positive Phase 2 results for mosliciguat, trading at $41.35, up 18.35%. Atara Biotherapeutics (ATRA) updated BLA resubmission plans, trading at $10.71, up 9.73%. PDS Biotech (PDSB) raised $22.55M in PIPE financing, trading at $0.29, up 33.21%.

Related tickers